CompletedPhase 2NCT00419770

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Studying Zygomycosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Principal Investigator: Brad Spellberg, MD
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Intervention: deferasirox(drug)
Enrollment: 20 target
Eligibility: 2 years · All sexes
Timeline: 2007 – 2010

Study locations (7)

City of Hope National Medical Center, Duarte, California, United States
UCSF, San Francisco, California, United States
University of Miami, Miami, Florida, United States
Duke University, Durham, North Carolina, United States
Summa Health Systems, Akron, Ohio, United States
MD Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Collaborators

Gilead Sciences · Astellas Pharma Inc · Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00419770 on ClinicalTrials.gov

Other trials for Zygomycosis

Additional recruiting or active studies for the same condition.

See all trials for Zygomycosis →

← Back to all trials